Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron Titration in T2DM and Obesity
NCT04617275Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity (7 arms), sponsored by Pfizer. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) by Severity at Day 112. Started Jan 2021; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04617275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617275.